Selecta Biosciences

Selecta Biosciences is an American clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Selecta Biosciences was founded in 2007 and is headquartered in Watertown, Massachusetts.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Selecta Biosciences balance sheet

Report period2018 2019 2020 2021 2022Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Selecta Biosciences cash flows

Report period2018 2019 2020 2021 2022Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Selecta Biosciences multipliers

Report period2018 2019 2020 2021 2022Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Selecta Biosciences profitability

Report period2018 2019 2020 2021 2022Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Selecta Biosciences assets
Selecta Biosciences cash flows

Selecta Biosciences dividend policy

The company doesn't provide dividend
Selecta Biosciences news
05.05.2022
Selecta Biosciences' GAAP net income for 3 months of 2022 was $28.778 million, compared to a loss of $24.597 million in the previous year. Revenue increased 3.1 times to $33.999 million from $11.05 million a year earlier.
Source: {source} pictogram ir.selectabio.com
Pictogram next
10.03.2022
Selecta Biosciences' GAAP loss for 2021 was $25.687 million, down 2.7 times from $68.876 million in the previous year. Revenue increased 5.1 times to $85.077 million from $16.597 million a year earlier.
Source: {source} pictogram ir.selectabio.com
Pictogram next
09.11.2021
Selecta Biosciences' GAAP loss for 9M 2021 was $37.926 million, down 29% from $53.43 million in the previous year. Revenue increased 11.9 times to $55.14 million from $4.646 million a year earlier.
Source: {source} pictogram ir.selectabio.com
Pictogram next
13.05.2021
Selecta Biosciences' GAAP loss for 3 months of 2021 was $24.597 million, up 25.4% from $19.62 million in the previous year. Revenues were $11.05 million. The company did not generate revenues a year earlier.
Source: {source} pictogram ir.selectabio.com
Pictogram next
All Selecta Biosciences news
General information
Company nameSelecta Biosciences
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address480 Arsenal Street Building 1 Watertown, MA 02472 United States
Mailing address480 Arsenal Street Building 1 Watertown, MA 02472 United States
Websitewww.selectabio.com
Information disclosurewww.sec.gov